The short answer
Routine biotin supplementation or testing is not established for everyone taking valproate. If hair loss develops, discuss an assessment before choosing high-dose biotin.
What this answer covers
Oral biotin (vitamin B7) during valproate treatment. Blood biotin and biotinidase activity are different measurements; enzyme changes are not a diagnosis of dietary deficiency.
- Supplement or preparation
- Biotin
- Medication ingredient
- valproate
What the studies show
One study of 20 children taking valproic acid found no significant difference in biotin levels or biotinidase activity compared with controls. A later adult study found associations between valproate, biotinidase activity and hair loss. These different measurements do not establish that everyone taking valproate becomes biotin deficient.
Hair loss deserves an assessment
Hair loss improved in three children after biotin was given, but there was no untreated comparison and their measured biotin status was normal. That report is a reason to discuss persistent hair loss with your clinician, not a proven treatment or dose to copy.
Before choosing a supplement
Discuss your diet, symptoms and the full supplement label with your care team. The evidence does not supply a routine valproate-specific biotin dose or monitoring schedule. Do not stop or reduce valproate yourself in an attempt to manage hair loss.
Tell the laboratory about biotin
Biotin can distort some blood-test results, including falsely low results on susceptible troponin tests. Tell the clinician and laboratory the product, dose and time you last took it. They can decide whether a test needs special handling; do not assume a standard waiting period works for every assay.
Evidence and practical considerations
Timing & monitoring
Current inspected evidence does not establish a routine biotin supplement requirement or universal biotin testing schedule for valproate users.
- Exact scope
- Oral biotin (vitamin B7) during valproate treatment. Blood biotin and biotinidase activity are different measurements; enzyme changes are not a diagnosis of dietary deficiency. with Valproate RxCUI 40254 IN. NLM identifies valproic acid and sodium valproate as related precise ingredients; oral valproic acid dissociates to valproate. This active-moiety bridge does not equate release kinetics, all salts, doses or routes.
- Medication form and route
- Oral
What remains uncertain
- Small observational studies and three uncontrolled hair-loss responses do not show that routine supplementation prevents a clinically important deficiency.
Factors that may matter: Exact preparation and route; Age and clinical indication; Baseline nutritional status; Other treatments.
Read the supporting source summaries
Source 1: Original clinical research
ebi.ac.uk · Source check Sep 10, 2026
Population: 20 children treated with valproic acid, 10 with carbamazepine and 75 matched healthy controls.
No significant between-group differences in biotin or biotinidase activity. Hair loss resolved in the three supplemented children despite normal measured status.
How this applies: Exact valproic acid exposure bridged to oral valproate; use only its arm. Does not establish universal depletion.
Small study; supplementation in three patients was uncontrolled. Improvement does not establish causality, routine need, prevention or an appropriate dose for others.
Source 2: Original clinical research
ebi.ac.uk · Source check Sep 10, 2026
Population: 75 people receiving valproate and 75 controls in a cross-sectional comparison.
Hair loss was reported more often in the valproate group, and biotinidase activity differed with hair-loss status.
How this applies: Exact valproate association, with medication formulation not fully characterized in the abstract. Not a supplementation requirement.
Association and enzyme activity do not demonstrate dietary biotin deficiency or that supplements correct hair loss. Full text returned an HTTP 200 challenge page, so only the original abstract is used.
Source 3: Current U.S. prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving oral valproic acid.
Recommends folic acid before conception and during pregnancy for women of childbearing potential. Protection against valproate-associated neural tube defects or reduced IQ is unknown. Warns of hyperammonemia and abrupt discontinuation. States no extent-of-absorption effect in the specified antacid study.
How this applies: Exact active-moiety safety and formulation-specific context. Valproate RxCUI 40254 IN. NLM identifies valproic acid and sodium valproate as related precise ingredients; oral valproic acid dissociates to valproate. This active-moiety bridge does not equate release kinetics, all salts, doses or routes.
Not proof of universal nutrient deficiency or of an interaction with each supplement. The antacid summary differs from the original 1982 abstract; that difference is retained.
Research assessment: · Open full citations ↗
Laboratory test interference
Biotin supplements can interfere with certain laboratory tests; tell the clinician and laboratory if you take them.
- Exact scope
- Oral biotin (vitamin B7) during valproate treatment. Blood biotin and biotinidase activity are different measurements; enzyme changes are not a diagnosis of dietary deficiency. with Valproate RxCUI 40254 IN. NLM identifies valproic acid and sodium valproate as related precise ingredients; oral valproic acid dissociates to valproate. This active-moiety bridge does not equate release kinetics, all salts, doses or routes.
- Medication form and route
- Oral
What remains uncertain
- This is an assay-specific biotin effect, not a demonstrated interaction with valproate or its blood-level assay.
Factors that may matter: Exact preparation and route; Age and clinical indication; Baseline nutritional status; Other treatments.
Read the supporting source summaries
Source 1: Regulatory laboratory safety communication
fda.gov · Source check Sep 10, 2026
Population: People taking biotin who undergo susceptible laboratory assays.
Biotin can cause incorrect results; FDA continues to receive reports of falsely low troponin results.
How this applies: Supplement-only counseling relevant if biotin is chosen; no valproate pharmacokinetic interaction is inferred.
Assay-specific, not every test and not a demonstrated interference with a valproate assay. No universal washout time is supplied here.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: d76d9ca963a4e377
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.